164 related articles for article (PubMed ID: 36582117)
1. Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer.
Saoudi Gonzalez N; López D; Gómez D; Ros J; Baraibar I; Salva F; Tabernero J; Élez E
Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):755-767. PubMed ID: 36582117
[TBL] [Abstract][Full Text] [Related]
2. The safety of monoclonal antibodies for treatment of colorectal cancer.
Berger MD; Lenz HJ
Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer.
Lo L; Patel D; Townsend AR; Price TJ
Expert Opin Drug Metab Toxicol; 2015; 11(12):1907-24. PubMed ID: 26572750
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
Zhang W; Gordon M; Lenz HJ
Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.
Françoso A; Simioni PU
Drug Des Devel Ther; 2017; 11():177-184. PubMed ID: 28138221
[TBL] [Abstract][Full Text] [Related]
7. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
8. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies.
Yoshida M; Shimura T; Sato M; Ebi M; Nakazawa T; Takeyama H; Joh T
J Cancer Res Clin Oncol; 2013 Mar; 139(3):367-78. PubMed ID: 23099994
[TBL] [Abstract][Full Text] [Related]
9. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
Battaglin F; Dadduzio V; Bergamo F; Manai C; Schirripa M; Lonardi S; Zagonel V; Loupakis F
Expert Opin Biol Ther; 2017 Oct; 17(10):1297-1308. PubMed ID: 28752777
[TBL] [Abstract][Full Text] [Related]
10. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
Normanno N; Tejpar S; Morgillo F; De Luca A; Van Cutsem E; Ciardiello F
Nat Rev Clin Oncol; 2009 Sep; 6(9):519-27. PubMed ID: 19636327
[TBL] [Abstract][Full Text] [Related]
11. The role of targeted therapy in the treatment of advanced colorectal cancer.
Fakih M
Curr Treat Options Oncol; 2008 Dec; 9(4-6):357-74. PubMed ID: 19238551
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
13. Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC).
Xiong F; Zhou YW; Hao YT; Wei GX; Chen XR; Qiu M
Expert Rev Gastroenterol Hepatol; 2024; 18(4-5):185-192. PubMed ID: 37705376
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review.
Koilakou S; Petrou P
Mol Diagn Ther; 2021 Nov; 25(6):715-734. PubMed ID: 34816395
[TBL] [Abstract][Full Text] [Related]
15. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
16. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
17. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
18. A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
Jackson C; Cunningham D
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S8-15. PubMed ID: 18361806
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
Abrams TA; Meyer G; Schrag D; Meyerhardt JA; Moloney J; Fuchs CS
J Natl Cancer Inst; 2014 Feb; 106(2):djt371. PubMed ID: 24511107
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
